Urticaria, exanthems, and other benign dermatologic reactions to smallpox vaccination in adults

Richard N. Greenberg; Robert H. Schosser; Elizabeth A. Plummer; Sara E. Roberts; Malissia A. Caldwell; Dana L. Hargis; David W. Rudy; Martin E. Evans; Robert J. Hopkins

doi:10.1086/382360

Urticaria, exanthems, and other benign dermatologic reactions to smallpox vaccination in adults

Richard N. Greenberg, Robert H. Schosser, Elizabeth A. Plummer, Sara E. Roberts, Malissia A. Caldwell, Dana L. Hargis, David W. Rudy, Martin E. Evans, Robert J. Hopkins

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A phase 1 smallpox vaccine trial involving 350 adult volunteers was conducted. Of these subjects, 250 were naive to vaccinia virus vaccine (i.e., "vaccinia naive"). Volunteers received a new cell-cultured smallpox vaccine or a live vaccinia virus vaccine. Nine self-limiting rashes (3.6%) were observed in the vaccinia-naive group. None of the vaccinia-experienced patients had a rash. Rashes appeared 6-19 days after vaccination and had 5 different clinical presentations. Five volunteers had urticarial rashes that resolved within 4-15 days 1 had an exanthem that lasted 20 days and 1 each presented with folliculitis, contact dermatitis, and erythematous papules found only on the hands and fingers. Volunteers reported pruritus tingling, and occasional headaches. Relief was obtained with antihistamine and acetaminophen therapy. No volunteer experienced fever or significant discomfort.

Original language	English
Pages (from-to)	958-965
Number of pages	8
Journal	Clinical Infectious Diseases
Volume	38
Issue number	7
DOIs	https://doi.org/10.1086/382360
State	Published - Apr 1 2004

Bibliographical note

Funding Information:
Financial support: DynPort Vaccine Company, which financed the vaccine trial; the US Department of Defense Joint Vaccine Acquisition Program (DAMD 17-98-C-8024); and the University of Kentucky (GCRC grant number M01-RR-02602).

Funding

Financial support: DynPort Vaccine Company, which financed the vaccine trial; the US Department of Defense Joint Vaccine Acquisition Program (DAMD 17-98-C-8024); and the University of Kentucky (GCRC grant number M01-RR-02602).

Funders	Funder number
DynPort Vaccine Company
GCRC	M01-RR-02602
US Department of Defense Joint Vaccine Acquisition Program	DAMD 17-98-C-8024
National Center for Research Resources	M01RR002602
University of Kentucky

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/382360

Cite this

@article{54d7b9e6f3bb45388fceb33b4532afc9,

title = "Urticaria, exanthems, and other benign dermatologic reactions to smallpox vaccination in adults",

abstract = "A phase 1 smallpox vaccine trial involving 350 adult volunteers was conducted. Of these subjects, 250 were naive to vaccinia virus vaccine (i.e., {"}vaccinia naive{"}). Volunteers received a new cell-cultured smallpox vaccine or a live vaccinia virus vaccine. Nine self-limiting rashes (3.6%) were observed in the vaccinia-naive group. None of the vaccinia-experienced patients had a rash. Rashes appeared 6-19 days after vaccination and had 5 different clinical presentations. Five volunteers had urticarial rashes that resolved within 4-15 days 1 had an exanthem that lasted 20 days and 1 each presented with folliculitis, contact dermatitis, and erythematous papules found only on the hands and fingers. Volunteers reported pruritus tingling, and occasional headaches. Relief was obtained with antihistamine and acetaminophen therapy. No volunteer experienced fever or significant discomfort.",

author = "Greenberg, {Richard N.} and Schosser, {Robert H.} and Plummer, {Elizabeth A.} and Roberts, {Sara E.} and Caldwell, {Malissia A.} and Hargis, {Dana L.} and Rudy, {David W.} and Evans, {Martin E.} and Hopkins, {Robert J.}",

note = "Funding Information: Financial support: DynPort Vaccine Company, which financed the vaccine trial; the US Department of Defense Joint Vaccine Acquisition Program (DAMD 17-98-C-8024); and the University of Kentucky (GCRC grant number M01-RR-02602).",

year = "2004",

month = apr,

day = "1",

doi = "10.1086/382360",

language = "English",

volume = "38",

pages = "958--965",

number = "7",

}

TY - JOUR

T1 - Urticaria, exanthems, and other benign dermatologic reactions to smallpox vaccination in adults

AU - Greenberg, Richard N.

AU - Schosser, Robert H.

AU - Plummer, Elizabeth A.

AU - Roberts, Sara E.

AU - Caldwell, Malissia A.

AU - Hargis, Dana L.

AU - Rudy, David W.

AU - Evans, Martin E.

AU - Hopkins, Robert J.

N1 - Funding Information: Financial support: DynPort Vaccine Company, which financed the vaccine trial; the US Department of Defense Joint Vaccine Acquisition Program (DAMD 17-98-C-8024); and the University of Kentucky (GCRC grant number M01-RR-02602).

PY - 2004/4/1

Y1 - 2004/4/1

N2 - A phase 1 smallpox vaccine trial involving 350 adult volunteers was conducted. Of these subjects, 250 were naive to vaccinia virus vaccine (i.e., "vaccinia naive"). Volunteers received a new cell-cultured smallpox vaccine or a live vaccinia virus vaccine. Nine self-limiting rashes (3.6%) were observed in the vaccinia-naive group. None of the vaccinia-experienced patients had a rash. Rashes appeared 6-19 days after vaccination and had 5 different clinical presentations. Five volunteers had urticarial rashes that resolved within 4-15 days 1 had an exanthem that lasted 20 days and 1 each presented with folliculitis, contact dermatitis, and erythematous papules found only on the hands and fingers. Volunteers reported pruritus tingling, and occasional headaches. Relief was obtained with antihistamine and acetaminophen therapy. No volunteer experienced fever or significant discomfort.

AB - A phase 1 smallpox vaccine trial involving 350 adult volunteers was conducted. Of these subjects, 250 were naive to vaccinia virus vaccine (i.e., "vaccinia naive"). Volunteers received a new cell-cultured smallpox vaccine or a live vaccinia virus vaccine. Nine self-limiting rashes (3.6%) were observed in the vaccinia-naive group. None of the vaccinia-experienced patients had a rash. Rashes appeared 6-19 days after vaccination and had 5 different clinical presentations. Five volunteers had urticarial rashes that resolved within 4-15 days 1 had an exanthem that lasted 20 days and 1 each presented with folliculitis, contact dermatitis, and erythematous papules found only on the hands and fingers. Volunteers reported pruritus tingling, and occasional headaches. Relief was obtained with antihistamine and acetaminophen therapy. No volunteer experienced fever or significant discomfort.

UR - http://www.scopus.com/inward/record.url?scp=1842509166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842509166&partnerID=8YFLogxK

U2 - 10.1086/382360

DO - 10.1086/382360

M3 - Article

C2 - 15034827

AN - SCOPUS:1842509166

SN - 1058-4838

VL - 38

SP - 958

EP - 965

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Urticaria, exanthems, and other benign dermatologic reactions to smallpox vaccination in adults

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this